-
Recent News
- FDA approves IND application for peanut allergen vaccine. Phase I study in peanut allergy patients to begin May 2022
- Peanut allergy vaccine takes big step forward with first human tests
- Saiba AG focuses on a future COVID-19 vaccine with advantages over first to market vaccine candidates
- Allergy Therapeutics secures virus-like particle (“VLP”) technology platform to broaden vaccine pipeline through licensing agreements with Saiba AG and DeepVax GmbH
- Saiba AG Selects AGC Biologics to Develop and Produce COVID-19 Vaccine
Archives